Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from AstraZeneca

AstraZeneca's Latest Drug Offers Hope For Millions Battling Hard-To-Control Blood Pressure

On Saturday, AstraZeneca Plc (NASDAQ:AZN) released full results from the BaxHTN Phase 3 trial evaluating baxdrostat. The company released the topline data in July.

Benzinga

New blood pressure pill ‘lowers risk of heart problems in 12 weeks’

IN FULL

The Independent UK

The new daily pill that lowers high blood pressure by ‘spectacular’ amounts

Baxdrostat, developed by AstraZeneca, could help 10 million people worldwide

The Independent UK

From analysis to the latest developments in health,
read the most diverse news in one place.

New daily pill offers hope for millions with hard to control high blood pressure

A phase III trial of Baxdrostat showed it significantly lowered blood pressure in patients whose levels remained high despite being on other drugs.

The Independent UK

Wes Streeting’s row with pharma firms grows as they reject NHS drug pricing offer

Drugmakers reject health secretary’s latest offer, meaning ‘unsustainable’ rebate scheme will stay in place

The Guardian - UK

J&J Commits $2 Billion To US Manufacturing Expansion Amid Threat Of Drug Tariffs

Johnson Johnson (NYSE:JNJ) is set to invest $2 billion in its North Carolina facilities, expanding its U.S. manufacturing operations. This move comes in response to potential drug import tariffs proposed by the Trump administration.

Benzinga

EuroMillions Result: 5 Stocks the £210M Lottery Winner Could Consider

French ticket-holder wins £210M EuroMillions on 19 Aug 2025, beating UK records. Grow wealth with AstraZeneca, Unilever, Shell, Microsoft, HSBC

International Business Times UK

Read news from The Economist, FT, and more,
with one subscription

Top executives’ pay in UK hits record high – reaching 122 times of average worker

It marks the fourth year in a row that chief executives have taken home a record amount

The Independent UK

Top executive pay in UK’s biggest firms hits new record as more take home £10m

Median pay for chief executive officers of FTSE 100 companies was £4.58 million in the 2024-2025 financial year.

Evening Standard

You can now give yourself an at-home flu vaccine

The nasal spray has been approved by the FDA since 2003

The Independent UK

Sanofi, Eli Lilly, Novo Nordisk, AstraZeneca Face Renewed Claims Of Conspiring To Restrict 340B Discounts

A federal appeals court has revived a proposed class action accusing four major drugmakers of conspiring to restrict a government-mandated drug discount program, allegedly driving up costs for safety-net hospitals and clinics serving low-income patients.

Benzinga

Shares in European drug companies hit four-month low as Trump tariffs loom

President repeats threat to bring in levies ‘within next week or so’ in attempt to get companies to move production to US

The Guardian - UK

Ministers take note: now is the moment to fight to keep AstraZeneca’s listing in London

One hopes cogs are turning in Westminster after Pascal Soriot’s affectionate talk of US at pharmaceutical giant’s half-year results

The Guardian - UK

FTSE 100 climbs as earnings cascade brings cheer

Shares of Games Workshop, AstraZeneca, Barclays and Entain moved higher.

Evening Standard

Get all your
news in one place.

100’s of premium titles.
One news app.

The Guardian - UK

AstraZeneca chief executive hails ‘vital importance of US’ as Trump tariffs loom

Pascal Soriot refuses to be drawn, however, on reports AZ could move its main stock market listing across the Atlantic

Benzinga

AstraZeneca Q2 Sales Beat Estimates On Strong Cancer Drugs Revenues, Reaffirms 2025 Outlook

AstraZeneca Plc (NASDAQ:AZN) on Tuesday reported second-quarter 2025 sales of $14.46 billion, up 12% year over year (+11% at constant currency), marginally beating the consensus of $14.07 billion, driven by double-digit growth in oncology and biopharmaceuticals.

Evening Standard

Cancer drug demand drives higher sales for AstraZeneca

Revenues from oncology products made up 43% of the company’s total sales.

The Independent UK

Business news live: UK food inflation surges again and FTSE 100 results with Greggs facing ‘near-term hurdles’

Stock market news and latest business and finance updates from Tuesday

Get all your
news in one place.

100’s of premium titles.
One news app.

Barchart

Unlocking Oncology’s Future: 3 Trending Cancer Biotech Stocks with ‘Strong Buy’ Ratings

Three emerging biotech companies — Elicio Therapeutics, Cellectis, and Autolus Therapeutics — are attracting “Strong Buy” analyst ratings in 2025 as major clinical, regulatory, and commercial catalysts position them for standout growth in the cancer treatment market.

Euronews

EU regulators give backing to first-of-its-kind inhaler that is more climate-friendly

Inhalers may be small, but they can make a big impact on the environment.

Benzinga

AstraZeneca Prepares Showdown With JNJ, Amgen With Phase 3 Win For Myasthenia Gravis Drug Candidate

AstraZeneca Plc (NASDAQ:AZN) on Thursday reported high-level results from the PREVAIL Phase 3 trial evaluating the safety and efficacy of gefurulimab in adults with generalized myasthenia gravis (gMG). The trial enrolled 260 patients.

Benzinga

Trump Tariffs Forces AstraZeneca To Bring Substantial Pharmaceutical Production To US

AstraZeneca plc (NASDAQ:AZN) announced on Tuesday that it will invest $50 billion in the United States by 2030.

International Business Times

AstraZeneca To Invest $50 Bn In The US As Tariff Threat Looms

British pharmaceutical giant AstraZeneca said Tuesday it would invest $50 billion in the United States by 2030 amid Donald Trump's threats to impose tariffs on the sector.

Euronews

AstraZeneca pledges $50bn investment in the US amid 200% tariff fears

British-Swedish pharmaceutical company AstraZeneca is expanding its presence in the US in a bid to boost sales in its largest market.

Fortune

AstraZeneca CEO Pascal Soriot on why he’s building in the U.S.: ‘Europe is losing ground’

Also: All the news and watercooler chat from Fortune.

1 … 3 4 5 6

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.